Trial Profile
A Prospective/Retrospective Non-Interventional Study of Vidaza® (Azacitidine) in Patients With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia With 20-30% Blasts and Multi-lineage Dysplasia in China
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms DIM Vidaza
- Sponsors Bristol-Myers Squibb
- 26 May 2023 Status changed from recruiting to completed.
- 13 May 2022 Planned End Date changed from 1 Mar 2024 to 30 Jun 2024.
- 13 May 2022 Planned primary completion date changed from 1 Mar 2024 to 30 Jun 2024.